Denali Therapeutics Inc.
corporate_fare Company Profile
Denali Therapeutics Inc. (NASDAQ:DNLI) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for DNLI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for DNLI spans 10-Q, 8-K, 10-K.
Recent high-impact activity:
- Denali Ends DNL151 Parkinson's Program After LUMA Trial Miss; Q4 AVLAYAH Guidance $30-32M
- Denali 10-Q: $70.1M Q3 Profit Is a PRV Gain; $1.0B Cash, $345.6M Nine-Month Burn
- Denali Swings to $70.1M Third-Quarter Net Income
- Denali Q2: AVLAYAH Launch Yields $3.6M Revenue; $195M PRV Sale Closes Post-Quarter; Pipeline Reshaped After Parkinson's Failure
- Denali Therapeutics Sells Rare Pediatric Disease Voucher for $195 Million
Financial Snapshot
Short Interest & Short Volume
9.91 days to coverFINRA reported short interest of 14,694,882 shares in DNLI as of the October 30, 2026 settlement, a 5.0% decrease from the prior period — about 9.9 days to cover at its recent average daily volume. On November 20, 2026, 62.2% of DNLI volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.